Bevacizumab-associated hypertension: Etiology, incidence, and management

Anti-Cancer Drugs

Volumn 20, Issue SPEC. ISS. 2, 2009, Pages

  Huerta, Sergio ^a   Li, Hsiao C ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

Author keywords

Avastin; Metastatic colon cancer; VEGF

Indexed keywords

AMLODIPINE; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; IRINOTECAN; VASCULOTROPIN;

ADD ON THERAPY; ADULT; ARTICLE; BEVACIZUMAB ASSOCIATED HYPERTENSION; BLEEDING; CASE REPORT; COLON CANCER; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INTESTINE PERFORATION; INTRAVENOUS PYELOGRAPHY; LIVER METASTASIS; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROSTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT PLANNING;

EID: 68049093187     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000349760.71997.90     Document Type: Article

References (11)

1. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
3. Lee JJ, Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 2007; 13:276-281.
4. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29:10-14.
5. Simpson D, Dunn C, Curran M, Goa KL. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 2003; 63:2127-2156.
6. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 2006; 63:334-337.
7. Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 2005; 280:9904-9912.
8. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49:186-193.
9. Fuchs CS, Marshall E, MItchell R, Wierxbicki RV, Ganju VM, Jeffery J, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: updated efficacy data. J Clin Oncol 2007; 25 (Suppl 18):170S.
10. Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2006; 33:S8-S14.
11. Saltz L, Clarke S, Diaz-Rubio E, Scheithauer WA, Figer A, Wong S, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. J Clin Oncol 2007; 25:4028.